Drug Type Small molecule drug, Diagnostic radiopharmaceuticals |
Synonyms 6-(1/2)(2-18F-fluoropropyl)-4-methylpyridin-2-amine, [18F](+/-)NOS |
Target- |
Mechanism PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alcohol Use Disorder | Phase 1 | US | 25 Apr 2023 | |
Inflammation | Phase 1 | US | 25 Apr 2023 | |
HIV Infections | Phase 1 | US | 07 Dec 2020 | |
Opioid abuse | Phase 1 | US | 07 Dec 2020 | |
Neuroinflammation | Phase 1 | US | 14 Aug 2019 | |
Parkinson Disease | Phase 1 | US | 14 Aug 2019 | |
Smoking | Phase 1 | US | 23 Oct 2018 | |
Pneumonia | Phase 1 | US | 01 Dec 2010 | |
Cardiac transplant rejection | Phase 1 | US | 01 Sep 2009 |
Early Phase 1 | 26 | (Dosimetry Group) | fserywmkva(ioznmwvkla) = ehrzrincqa fseqiadzri (ypyaqknckp, ehymgwjkdt - bqxwekvyox) View more | - | 07 Aug 2020 | ||
(Kinetic Analysis Group) | fserywmkva(ioznmwvkla) = owzawqyrle fseqiadzri (ypyaqknckp, wumhcirlva - dtjfoqxvso) View more |